A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

With heart valve disease on the rise in India, cardiac experts at Apollo Hospitals Navi Mumbai (AHNM) have highlighted the ...

which is present in approximately 50% of heart failure cases. If LVEF is 40% or less a patient is considered to have heart failure with reduced ejection fraction (HFrEF), sometimes known as ...

High-dose ifetroban improved LVEF by 3.3%, with a 5.4% gain compared ... a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients.

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from ...